Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 93.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 9,513 shares of the biopharmaceutical company’s stock after selling 128,777 shares during the period. Thrivent Financial for Lutherans’ holdings in Regeneron Pharmaceuticals were worth $4,994,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. MASTERINVEST Kapitalanlage GmbH acquired a new position in Regeneron Pharmaceuticals during the second quarter valued at $1,138,000. Cim Investment Management Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 99.6% in the 2nd quarter. Cim Investment Management Inc. now owns 920 shares of the biopharmaceutical company’s stock valued at $483,000 after buying an additional 459 shares during the period. Monarch Capital Management Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 67.0% in the second quarter. Monarch Capital Management Inc. now owns 2,345 shares of the biopharmaceutical company’s stock worth $1,231,000 after buying an additional 941 shares during the last quarter. Geneos Wealth Management Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 3.0% in the second quarter. Geneos Wealth Management Inc. now owns 780 shares of the biopharmaceutical company’s stock worth $410,000 after buying an additional 23 shares during the last quarter. Finally, Westwood Holdings Group Inc. raised its position in Regeneron Pharmaceuticals by 17.0% during the second quarter. Westwood Holdings Group Inc. now owns 13,556 shares of the biopharmaceutical company’s stock valued at $7,117,000 after acquiring an additional 1,974 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the sale, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. The trade was a 9.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Christine A. Poon sold 6,500 shares of the company’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the sale, the director directly owned 2,352 shares of the company’s stock, valued at $1,538,843.04. The trade was a 73.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 7.02% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Raymond James Financial upgraded Regeneron Pharmaceuticals to a “moderate buy” rating in a research report on Tuesday, September 2nd. UBS Group increased their price target on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a report on Friday, November 7th. Morgan Stanley lifted their price objective on shares of Regeneron Pharmaceuticals from $767.00 to $768.00 and gave the company an “equal weight” rating in a report on Friday, December 12th. Jefferies Financial Group increased their target price on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a research note on Wednesday, August 27th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $779.45.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $767.96 on Friday. The firm’s fifty day simple moving average is $682.40 and its two-hundred day simple moving average is $599.63. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $790.98. The company has a market cap of $80.71 billion, a price-to-earnings ratio of 18.39, a PEG ratio of 2.15 and a beta of 0.37. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping the consensus estimate of $9.73 by $2.10. The firm had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $12.46 EPS. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Thursday, November 20th were given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.5%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.43%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.